Biothera thinks its Imprime PGG beta-glucan, a soluble carbohydrate, could
be combined with complement-fixing MAbs to improve their efficacy compared to
the MAbs alone in some cancers.
Last week, the company's scientists published preclinical data in Cancer
Research demonstrating significantly increased survival in murine xenograft
models of non-small cell lung cancer (NSCLC) given Erbitux cetuximab in combination
with the yeast-derived beta-glucan compared with mice given Erbitux alone. Animals
given